What is the recommended cefdinir (Omnicef) dosing for an adult or pediatric patient with a bacterial infection and potential impaired renal function?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: February 4, 2026View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Cefdinir Dosing for Bacterial Infections

For adults and adolescents with bacterial infections, administer cefdinir 300 mg orally twice daily or 600 mg once daily for 5-10 days depending on the infection type; for pediatric patients (6 months-12 years), use 7 mg/kg every 12 hours or 14 mg/kg once daily (maximum 600 mg/day), with dose adjustments required for renal impairment. 1

Adult and Adolescent Dosing

Standard Dosing (Normal Renal Function)

  • 300 mg orally twice daily OR 600 mg once daily for most infections 1, 2
  • Duration: 5-10 days depending on infection type 1
  • May be administered without regard to meals 1

Renal Impairment Adjustments

For creatinine clearance <30 mL/min:

  • Reduce dose to 300 mg once daily 1
  • Use the Cockcroft-Gault formula to estimate creatinine clearance in adults 1:
    • Males: CLcr = (weight × [140 - age]) / (72 × serum creatinine)
    • Females: CLcr = 0.85 × above value 1

For hemodialysis patients:

  • Initial dose: 300 mg every other day 1
  • At conclusion of each hemodialysis session: give 300 mg 1
  • Subsequent doses: 300 mg every other day 1
  • Note: Approximately 60% of cefdinir is removed by 3-4 hours of hemodialysis 3

Pediatric Dosing (Age 6 Months Through 12 Years)

Standard Dosing by Infection Type

Total daily dose: 14 mg/kg (maximum 600 mg/day) 1

Infection Type Dosing Regimen Duration
Acute otitis media 7 mg/kg q12h OR 14 mg/kg q24h 5-10 days (once daily) or 10 days (twice daily) [1]
Acute sinusitis 7 mg/kg q12h OR 14 mg/kg q24h 10 days [1]
Pharyngitis/tonsillitis 7 mg/kg q12h OR 14 mg/kg q24h 5-10 days (once daily) or 10 days (twice daily) [1]
Skin/skin structure infections 7 mg/kg q12h only 10 days [1]

Important caveat: Once-daily dosing has NOT been studied for skin infections, so twice-daily dosing must be used for this indication 1

Weight-Based Dosing Chart

For pediatric patients ≥43 kg: use maximum adult dose of 600 mg/day 1

Using 125 mg/5 mL suspension:

  • 9 kg (20 lbs): 2.5 mL q12h or 5 mL q24h 1
  • 18 kg (40 lbs): 5 mL q12h or 10 mL q24h 1
  • 27 kg (60 lbs): 7.5 mL q12h or 15 mL q24h 1
  • 36 kg (80 lbs): 10 mL q12h or 20 mL q24h 1

Using 250 mg/5 mL suspension:

  • 18 kg (40 lbs): 2.5 mL q12h or 5 mL q24h 1
  • 27 kg (60 lbs): 3.75 mL q12h or 7.5 mL q24h 1
  • 36 kg (80 lbs): 5 mL q12h or 10 mL q24h 1

Pediatric Renal Impairment

For creatinine clearance <30 mL/min/1.73 m²:

  • Reduce dose to 7 mg/kg once daily (maximum 300 mg) 1
  • Use modified Schwartz formula to estimate pediatric creatinine clearance 1:
    • CLcr = K × (body length in cm) / serum creatinine
    • K = 0.55 for children >1 year 1
    • K = 0.45 for infants up to 1 year 1

For pediatric hemodialysis patients:

  • 7 mg/kg every other day 1
  • At conclusion of each hemodialysis session: give 7 mg/kg 1
  • Subsequent doses: 7 mg/kg every other day 1

Clinical Considerations

Antimicrobial Spectrum

  • Excellent activity against common respiratory pathogens: Streptococcus pneumoniae (penicillin-susceptible), Haemophilus influenzae, and Moraxella catarrhalis 2, 4
  • Stable to hydrolysis by common plasmid-mediated beta-lactamases 4, 5
  • Particularly useful in areas with elevated beta-lactamase production rates 2

Safety Profile

  • Most common adverse event: mild diarrhea (approximately 20% of patients) 6
  • Generally well tolerated across all age groups 4
  • Discontinuation rates due to adverse events similar to comparator agents 4
  • Superior taste/palatability of oral suspension compared to other antimicrobials 2

Important Caveats

  • Antibiotic stewardship: Minimize frequency and duration of cephalosporin use to reduce Clostridioides difficile infection risk 7
  • Discontinue inciting antibiotics as soon as possible when CDI is suspected 7
  • Suspension stable for 10 days after reconstitution at room temperature; discard unused portion after this period 1
  • Pharmacokinetic parameters in children similar to adults when using equivalent mg/m² doses 5

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.